Citi lowered the firm’s price target on Biomea Fusion (BMEA) to $9 from $22 and keeps a Buy rating on the shares. The firm cites the company’s strategic realignment for the target cut. With the focus now metabolic disease, Biomea is no longer pursuing oncology, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMEA:
- Biomea Fusion’s Phase 2 Trial: A New Hope for Type 1 Diabetes Treatment
- Biomea Fusion’s BMF-219 Study: A Potential Game-Changer for Type 2 Diabetes
- Biomea Fusion’s BMF-219 Study Update: Implications for Investors
- Largest borrow rate increases among liquid names
- Biomea Fusion price target lowered to $4 from $18 at H.C. Wainwright